CRS with Nasal Polyps - setting the new gold standard: (PART 3) Overcoming challenges in future care

For decades, surgery of the nose and paranasal sinuses has been the gold standard for the treatment of patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) that are uncontrolled by medical therapy. However, surgery isn't a Panacea. In severe patients, symptoms may return and the disease becomes uncontrolled even with appropriate medical therapy., including surgery. However, have we now reached a stage where new drugs can offer a paradigm shift in the treatment of CRS with Nasal Polyps where surgery is no longer considered the gold standard.

No surgery…. or nose surgery? That is the question. This is the EUFOREA Innovation forum debate on CRS with Nasal Polyps - setting the new gold standard

Chronic Rhinosinusitis with nasal polyps or CRS with NP is a chronic inflammatory condition of the nose and the paranasal sinuses which causes a significant impact on the lives of those
patients affected. It’s estimated to affect about one to four percent of the general population and about 25 to 30 percent of patients with chronic Rhinosinusitis.

There is an underlying inflammatory process at work which is called type 2 inflammation. This means that CRS with NP often presents with comorbidities including asthma and allergies. Patients suffering from CRS with NP experience symptoms of nasal obstruction, smell dysfunction with anosmia, continuous nasal discharge and facial pain. All of these have a massive impact on the patient's quality of life and living with this condition can also profoundly affect people's mental health. Psychological symptoms including depression are common. Additionally, with so many people affected by the disease there is also a significant economic impact to including the cost of providing recurrent Health Care, absenteeism from work and loss work productivity. Therefore it is vital that we continually improve the care that we can offer to patients with CRS with NP and in turn improve their quality of life.

In PART 3 of this innovation forum, we’ll address how healthcare providers can overcome the challenges in future care for patients with CRSwNP, including:

00:28 What are the current obstacles for using these biologics in clinical practice?

03:40 What are patient concerns about the safety of these drugs?

11:59 What can be done to lower the costs of biologics?

15:01 Final thoughts

---------------------------------------------------------------------------------------------------------------------------------------------------------

Download the FREE EUFOREA Chronic Rhinosinusitis Pocket guide here:

2nd Annual Chronic Rhinosinusitis with Nasal Polyps Awareness Day (20 April 2023):

Stay in touch for further news from EUFOREA!

Follow us on ⬇️
​
📌 EUFOREA is an international non-profit organisation forming an alliance of all stakeholders dedicated to reducing the prevalence and burden of allergies and airway diseases by implementing optimal patient care through education, research and advocacy.
--------------------------------------------------------------------------------------------------------------------------
Subscribe to our YouTube Channel for our latest videos on Allergies and Airway Diseases
--------------------------------------------------------------------------------------------------------------------------
Get in touch with EUFOREA team for any questions

#EUFOREA